小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染疗效观察

The therapeutic efficacy of pediatric paracetamol combined with ribavirin aerosol in children with acute upper respiratory tract infection

目的探讨小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染的疗效。方法选择浙江省台州市立医院儿科门诊确诊为急性上呼吸道感染患儿138例，按就诊顺序奇偶数分为治疗组和对照组，各69例。对照组口服利巴韦林颗粒，10-15 mg/（kg·d），分3-4次，连用3 d10治疗组口服小儿氨酚黄那敏颗粒，1-3岁0.5-1 包,3次/d，4-6岁1-1.5包,3次/d，7-9岁1.5-2包,3次/d；同时给予利巴韦林气雾剂，首次使用1 h内喷4次，1次2-3揿，以后每隔1 h喷1次，1次2-3揿，2 d以后4次/d，1次2-3揿，儿童每日平均剂量15-20 mg，连用3 d10比较2组治疗5 d后疗效、热退时间、鼻塞缓解时间、流涕缓解时间及咳嗽缓解时间。结果治疗5 d后，治疗组有效率明显高于对照组[95.7%（66/69）比76.8%（53/69）] ，差异有统计学意义（χ^2= 13.80，P＜0.05）;治疗组患儿热退时间、鼻塞缓解时间、流涕缓解时间及咳嗽缓解时间均短于对照组[（2.4±0.5）d比（2.9±0.6）d、（2.8±0.7）d比（3.8±0.9）d、（3.2±0.8）d比（3.8±0.9）d、（3.6±1.2）d比（4.9±1.3）d，P＜0.01］。治疗期间对照组有1例出现白细胞减少，治疗组未出现不良反应。结论小儿氨酚黄那敏颗粒联合利巴韦林气雾剂治疗急性上呼吸道感染疗效确切。

Objective To explore the therapeutic efficacy of pediatric paracetamol combined with ribavirin aerosol in children with acute upper respiratory tract infection. MethodsOne hundred and thirtyeight children with acute upper respiratory tract infection were divided into control group（69 cases） and the treatment group（69 cases）. Patients in control group were given ribavirin granules. Patients in treatment group were given pediatric paracetamol. Thetherapeutic effects in both groups were evaluated after 5 days. Results After treatment, the effective rate of the treatment group was significantly higher than that of the control group [95.7%（66/69） vs 76.8%（53/69）],there was a statistically significant difference（χ^2=13.80,P〈0.05）. After treatment, the fever lasting time, runny nose relief time, stuffy nose remission time and cough relief time in the treatment group were shorter than those in the control group[（2.4±0.5）d vs （2.9±0.6）d,（2.8±0.7）d vs （3.8±0.9）d,（3.2±0.8）d vs （3.8±0.9）d,（3.6±1.2）d vs （4.9±1.3）d]; there were statistically significant differences（P〈0.01）. During the treatment, the control group had 1 cases of leukopenia and the treatment group had no adverse reactions. ConclusionPediatric paracetamol combined with ribavirin aerosol are effective in the treatment of acute upper respiratory tract infection in children.